These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15768345)

  • 1. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
    Kresina TF; Bruce RD; Cargill VA; Cheever LW
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating hepatitis C virus infection in active substance users.
    Sylvestre DL
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S321-4. PubMed ID: 15768341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
    Cullen W; Stanley J; Langton D; Kelly Y; Bury G
    Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
    Doab A; Treloar C; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and treatment of hepatitis C in illicit drug users].
    Sakoman S
    Acta Med Croatica; 2009 Dec; 63(5):437-42. PubMed ID: 20198904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
    Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection.
    Dore GJ; Thomas DL
    Semin Liver Dis; 2005 Feb; 25(1):18-32. PubMed ID: 15731995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.
    Sylvestre DL; Litwin AH; Clements BJ; Gourevitch MN
    J Subst Abuse Treat; 2005 Oct; 29(3):159-65. PubMed ID: 16183464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.
    Zeiler I; Langlands T; Murray JM; Ritter A
    Drug Alcohol Depend; 2010 Aug; 110(3):228-33. PubMed ID: 20430537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating HCV services for drug users: a model to improve engagement and outcomes.
    Sylvestre DL; Zweben JE
    Int J Drug Policy; 2007 Oct; 18(5):406-10. PubMed ID: 17854729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
    Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
    J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment.
    Sulkowski MS; Thomas DL
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S263-9. PubMed ID: 15768333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for hepatitis C virus infection among current injection drug users in Australia.
    Matthews G; Kronborg IJ; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S325-9. PubMed ID: 15768342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
    Strauss SM; Astone JM; Jarlais DD; Hagan H
    Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
    Hagan H; Strauss SM; Astone JM; Des Jarlais DC
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
    Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
    Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.